

Supplementary Table 1: Type 2 diabetes risk loci genotyped in Diabetes Prevent

Genetic Locus	SNP typed	Alleles (Risk/ Other)	Strand	OR	Study	Euro AA N (%)
<i>TCF7L2</i>	rs7903146	T/C	+	1.37	DIAGRAM	178 (11)
<i>CDKN2A/2B</i>	rs10811661	T/C	+	1.26	DIAGRAM	1158 (73)
<i>CDKAL1</i>	rs7754840	C/G	+	1.25	DIAGRAM	160 (10)
<i>PPARG</i>	rs1801282	C/G	+	1.18	DIAGRAM	<15
<i>HHEX</i>	rs1111875	C/T	-	1.17	DIAGRAM	572 (36)
<i>IGF2BP2</i>	rs1470579	C/A	+	1.17	DIAGRAM	189 (12)
<i>KCNJ11</i>	rs5219	T/C	+	1.16	DIAGRAM	601 (38)
<i>SLC30A8</i>	rs13266634	C/T	+	1.15	DIAGRAM	811 (51)
<i>THADA</i>	rs7578597	A/G	-	1.15	DIAGRAM	1308 (82)
<i>CENTD2</i>	rs1552224	A/C	-	1.14	DIAGRAM+	1206 (76)
<i>NOTCH2</i>	rs10923931	T/G	+	1.13	DIAGRAM	17 (1)
<i>ADCY5</i>	rs11708067	A/G	+	1.12	MAGIC	1013 (64)
<i>WFS1</i>	rs10010131	G/A	+	1.11	DIAGRAM	611 (38)
<i>CDC123</i>	rs4747969	C/T	+	1.11	DIAGRAM	57 (4)
<i>IRS1</i>	rs7578326	A/G	+	1.11	DIAGRAM+	712 (45)
<i>CHCHD9</i>	rs13292136	C/T	+	1.11	DIAGRAM+	1421 (89)
<i>JAZF1</i>	rs864745	G/A	+	1.10	DIAGRAM	372 (23)
<i>HNF1B</i>	rs757210	T/C	-	1.10	DIAGRAM	261 (16)
<i>HMGA2</i>	rs1531343	C/G	+	1.10	DIAGRAM+	25 (2)
<i>ADAMTS9</i>	rs4607103	C/T	+	1.09	DIAGRAM	838 (53)
<i>TSPAN8</i>	rs7961581	C/T	+	1.09	DIAGRAM	155 (10)
<i>MTNR1B</i>	rs10830963	G/C	+	1.09	MAGIC	133 (8)
<i>BCL11A</i>	rs243021	A/G	-	1.08	DIAGRAM+	368 (23)
<i>SLC22A18AS</i>	rs231362	G/A	-	1.08	DIAGRAM+	449 (28)
<i>ZBED3</i>	rs4457053	G/A	+	1.08	DIAGRAM+	144 (9)
<i>PROX1</i>	rs340874	C/T	-	1.07	MAGIC	479 (30)
<i>GCK</i>	rs917793	T/A	-	1.07	MAGIC	65 (4)
<i>TSGA13</i>	rs972283	G/A	+	1.07	DIAGRAM+	461 (29)
<i>VPS33B</i>	rs8042680	A/C	+	1.07	DIAGRAM+	175 (11)
<i>HNF1A</i>	rs7957197	T/A	+	1.07	DIAGRAM+	1065 (67)
<i>DGKB</i>	rs2191349	T/G	+	1.06	MAGIC	506 (32)
<i>GCKR</i>	rs780094	C/T	-	1.06	MAGIC	563 (35)
<i>PLEKHF2</i>	rs896854	T/C	-	1.06	DIAGRAM+	412 (26)
<i>BCL2A1</i>	rs11634397	G/A	+	1.06	DIAGRAM+	660 (41)

SNP= single nucleotide polymorphism

OR= Odds ratio reported by the study listed

A= risk allele
a= other allele

Where cell contents include <15 individuals, no exact number is shown per DPP policy

tion Program participants and genotype frequencies in each ethnic group

European descent		African American			Hispanic		
Aa	aa	AA	Aa	aa	AA	Aa	aa
N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)
716 (45)	699 (44)	55 (10)	247 (43)	272 (47)	33 (7)	153 (33)	280 (60)
391 (25)	46 (3)	512 (88)	65 (11)	<15	349 (75)	112 (24)	<15
701 (44)	734 (46)	184 (32)	293 (51)	102 (18)	58 (12)	192 (41)	216 (46)
308 (19)	1276 (80)		22 (4)	557 (96)	<15	73 (16)	391 (84)
774 (49)	249 (16)	346 (60)	200 (35)	33 (6)	196 (42)	217 (47)	53 (11)
650 (41)	756 (47)	326 (56)	204 (35)	49 (9)	46 (10)	190 (41)	230 (49)
785 (49)	209 (13)	491 (85)	84 (15)	<15	181 (39)	227 (49)	58 (12)
653 (41)	131 (8)	457 (79)	115 (20)	<15	278 (60)	158 (34)	30 (6)
276 (17)	<15	316 (55)	215 (37)	48 (8)	396 (85)	70 (15)	
364 (23)	25 (2)	551 (95)	27 (5)	<15	399 (86)	64 (14)	<15
304 (19)	1274 (80)	68 (12)	251 (43)	260 (45)	<15	99 (21)	362 (78)
510 (32)	72 (5)	434 (75)	128 (22)	17 (3)	284 (61)	156 (34)	26 (6)
744 (47)	240 (15)	264 (46)	252 (44)	63 (11)	233 (50)	193 (41)	40 (9)
485 (30)	1053 (66)	41 (7)	200 (35)	338 (58)	24 (5)	180 (39)	262 (56)
687 (43)	196 (12)	200 (35)	279 (48)	100 (17)	272 (58)	155 (33)	39 (8)
170 (11)	<15	488 (84)	87 (15)	<15	375 (81)	85 (18)	<15
808 (51)	415 (26)	29 (5)	221 (38)	329 (57)	64 (14)	221 (47)	181 (39)
719 (45)	615 (39)	160 (28)	290 (50)	129 (22)	56 (12)	209 (45)	201 (43)
318 (20)	1252 (79)	82 (14)	276 (48)	221 (38)	<15	90 (19)	370 (79)
651 (41)	106 (7)	294 (51)	236 (41)	49 (9)	233 (50)	192 (41)	41 (9)
653 (41)	787 (49)	22 (4)	192 (33)	365 (63)	23 (5)	161 (35)	282 (61)
654 (41)	808 (51)	<15	93 (16)	480 (83)	34 (7)	145 (31)	287 (62)
804 (50)	423 (27)	91 (16)	264 (46)	224 (39)	148 (32)	218 (47)	100 (22)
812 (51)	334 (21)	344 (59)	212 (37)	23 (4)	213 (46)	194 (42)	59 (13)
721 (45)	730 (46)	23 (4)	178 (31)	378 (65)	66 (14)	182 (39)	218 (47)
825 (52)	291 (18)	31 (5)	167 (29)	381 (66)	78 (17)	228 (49)	160 (34)
486 (31)	1044 (66)	29 (5)	216 (37)	334 (58)	44 (9)	209 (45)	213 (46)
795 (50)	339 (21)	397 (69)	164 (28)	18 (3)	168 (36)	224 (48)	74 (16)
726 (46)	694 (44)	419 (72)	146 (25)	<15	223 (48)	179 (38)	64 (14)
470 (30)	60 (4)	385 (67)	171 (30)	23 (4)	361 (78)	97 (21)	<15
773 (49)	316 (20)	187 (32)	295 (51)	97 (17)	113 (24)	223 (48)	130 (28)
778 (49)	254 (16)	388 (67)	170 (29)	21 (4)	166 (36)	247 (53)	53 (11)
789 (50)	394 (25)	276 (48)	250 (43)	53 (9)	105 (23)	233 (50)	128 (28)
740 (46)	195 (12)	106 (18)	290 (50)	183 (32)	165 (35)	216 (46)	85 (18)

Asian/Pacific islander			American Indian		
AA	Aa	aa	AA	Aa	aa
N (%)	N (%)	N (%)	N (%)	N (%)	N (%)
<15	34 (28)	87 (71)	<15	19 (24)	60 (75)
56 (46)	52 (42)	15 (12)		66 (83)	<15
17 (14)	64 (52)	42 (34)	<15	30 (38)	41 (51)
<15	20 (16)	102 (83)	<15	28 (35)	50 (63)
20 (16)	51 (42)	52 (42)	20 (25)	35 (44)	25 (31)
<15	50 (41)	59 (48)	<15	27 (34)	47 (59)
44 (36)	61 (50)	18 (15)	32 (40)	34 (43)	<15
46 (37)	65 (53)	<15	53 (66)	23 (29)	<15
109 (89)	12 (10)	<15	77 (96)	<15	
102 (83)	21 (17)		72 (90)	<15	
<15	20 (16)	102 (83)	<15	<15	67 (84)
102 (83)	20 (16)	<15	38 (48)	36 (45)	<15
85 (69)	31 (25)	<15	61 (76)	17 (21)	<15
<15	51 (42)	62 (50)	<15	29 (36)	50 (63)
90 (73)	30 (24)	<15	63 (79)	15 (19)	<15
99 (81)	23 (19)	<15	46 (58)	24 (30)	<15
<15	36 (29)	76 (62)	<15	35 (44)	37 (46)
19 (15)	55 (45)	49 (40)	<15	37 (46)	37 (46)
<15	24 (20)	98 (80)		<15	76 (95)
37 (30)	62 (50)	24 (20)	38 (48)	36 (45)	<15
<15	47 (38)	66 (54)		<15	70 (87)
23 (19)	55 (45)	45 (37)	<15	31 (39)	46 (58)
43 (35)	62 (50)	18 (15)	38 (48)	31 (39)	<15
85 (69)	35 (29)	<15	51 (64)	25 (31)	<15
<15	26 (21)	92 (75)	<15	38 (48)	31 (39)
23 (19)	57 (46)	43 (35)	<15	33 (41)	35 (44)
<15	42 (34)	76 (62)	18 (23)	41 (51)	21 (26)
50 (41)	64 (52)	<15	21 (26)	39 (49)	20 (25)
97 (79)	21 (17)	<15	62 (78)	15 (19)	<15
<15	113 (92)		75 (94)	<15	<15
51 (42)	56 (46)	16 (13)	<15	31 (39)	45 (56)
57 (46)	51 (42)	15 (12)	65 (81)	13 (16)	<15
15 (12)	61 (50)	47 (38)	16 (20)	43 (54)	21 (26)
<15	46 (37)	67 (55)	32 (40)	40 (50)	<15

Supplementary Table 2: Progression to diabetes and regression to normal glucose re

Progression to diabetes	Caucasian (n=1595)			African American (n=577)		
	HR	95% CI	P	HR	95% CI	P
Weighted Genetic Risk Score (per risk allele)	1.03	(1.00-1.06)	0.04	0.98	(0.94-1.03)	0.50
Metformin (vs Placebo)	0.74	(0.57-0.97)	0.03	0.62	(0.41-0.92)	0.02
Lifestyle (vs Placebo)	0.52	(0.39-0.69)	<0.0001	0.38	(0.24-0.61)	<0.0001
Female (vs Male)	1.07	(0.84-1.37)	0.58	0.88	(0.59-1.32)	0.54
Age at Randomization (y)	1.01	(1.00-1.02)	0.10	0.99	(0.97-1.01)	0.23
Waist (kg)	1.03	(1.02-1.03)	<0.0001	1.01	(1.00-1.03)	0.04
Regression to NGR	Caucasian (n=1251)			African American (n=480)		
	HR	95% CI	P	HR	95% CI	P
Weighted Genetic Risk Score (per risk allele)	0.95	(0.92-0.98)	0	0.93	(0.88-0.99)	0.01
Metformin (vs Placebo)	0.94	(0.67-1.32)	0.71	2.40	(1.38-4.17)	0
Lifestyle (vs Placebo)	2.35	(1.74-3.17)	<0.0001	2.63	(1.52-4.56)	0
Female (vs Male)	0.78	(0.60-1.01)	0.06	0.89	(0.55-1.43)	0.63
Age at Randomization (y)	0.98	(0.97-0.99)	0	0.99	(0.96-1.01)	0.17
Waist (kg)	0.99	(0.98-1.00)	0.03	0.97	(0.96-0.99)	0

gulation (NGR) in Diabetes Prevention Program participants by ethnic group

Hispanic (n=466)			Asian and Pac Is (n=123)			American Indians (n=80)		
HR	95% CI	P	HR	95% CI	P	HR	95% CI	P
1.06	(1.01-1.12)	0.03	1.09	(0.97-1.22)	0.15	0.92	(0.79-1.08)	0.31
0.74	(0.46-1.19)	0.22	0.52	(0.20-1.33)	0.17	0.52	(0.14-1.92)	0.33
0.38	(0.22-0.66)	0	0.33	(0.13-0.81)	0.02	0.31	(0.08-1.23)	0.09
0.84	(0.54-1.31)	0.44	0.97	(0.43-2.2)	0.94			
1.00	(0.98-1.02)	0.69	1.00	(0.96-1.04)	0.95	1.04	(0.98-1.10)	0.20
1.03	(1.01-1.04)	0	1.03	(0.99-1.06)	0.14	1.01	(0.97-1.04)	0.76
Hispanic (n=367)			Asian and Pac Is (n=106)			American Indians (n=48)		
HR	95% CI	P	HR	95% CI	P	HR	95% CI	P
0.98	(0.92-1.04)	0.45	0.91	(0.80-1.04)	0.16	1.05	(0.85-1.30)	0.67
1.47	(0.79-2.75)	0.23	1.47	(0.30-7.32)	0.64	0.10	(0.01-2.30)	0.15
2.40	(1.35-4.30)	0	2.46	(0.64-9.43)	0.19	0.65	(0.15-2.81)	0.56
0.80	(0.49-1.29)	0.35	0.88	(0.31-2.48)	0.81	2.68	(0.24-31.3)	0.43
0.97	(0.95-0.99)	0.01	1.00	(0.95-1.06)	0.99	1.02	(0.95-1.10)	0.61
0.99	(0.97-1.00)	0.13	0.96	(0.92-1.01)	0.14	0.93	(0.87-0.99)	0.02

Supplementary Table 3: Progression to diabetes using a genetic risk score (

Variables	Clinical model	
	HR (95% CI)	P-value
Weighted Genetic Risk Score (per allele)	1.01 (0.99-1.03)	0.35
Metformin (vs Placebo)	0.66 (0.54-0.80)	<0.0001
Lifestyle (vs Placebo)	0.43 (0.35-0.54)	<0.0001
Female (vs Male)	1.09 (0.89-1.34)	0.39
African Am (vs Caucasian)	1.09 (0.86-1.38)	0.48
Hispanic (vs Caucasian)	1.08 (0.85-1.37)	0.54
Asian/Pacific Islanders (vs Caucasian)	1.25 (0.83-1.88)	0.29
Am Ind (vs Caucasian)	1.34 (0.78-2.33)	0.29
Family Hx of DM	0.94 (0.78-1.13)	0.52
Age at Randomization (per year)	1.00 (0.99-1.01)	0.78
BMI (per kg/m ²)	1.01 (1.01-1.03)	0
Fasting Plasma glucose (per mg/dL)	1.09 (1.08-1.10)	<0.0001
Hypertension (y/n)	1.15 (0.94-1.40)	0.18
HDL (per mg/dL)	1.00 (0.99-1.01)	0.96
Log Triglycerides (per mg/dL)	1.47 (1.21-1.77)	<0.0001
Waist (per cm)	-	
2-Hr Plasma glucose (per mg/dL)	-	
Log Insulinogenic index (per unit)	-	
Log Fasting Insulin (per uU/mL)	-	
Log ALT (per IU/L)	-	
Log CRP (per mg/dL)	-	

(GRS) and a set a 'clinical' or 'physiological' variables

Physiological model	
HR (95% CI)	P-value
1.01 (0.99-1.04)	0.29
0.64 (0.53-0.78)	<0.0001
0.42 (0.34-0.52)	<0.0001
1.10 (0.88-1.37)	0.4
1.02 (0.81-1.29)	0.88
1.16 (0.90-1.49)	0.25
1.40 (0.92-2.11)	0.11
1.15 (0.65-2.02)	0.63
-	
1.00 (0.99-1.01)	0.95
-	
1.07 (1.06-1.08)	<0.0001
-	
-	
-	
1.01 (1.01-1.02)	0
1.02 (1.02-1.03)	<0.0001
0.42 (0.31-0.58)	<0.0001
1.19 (0.99-1.42)	0.07
1.02 (0.86-1.22)	0.79
1.07 (0.97-1.17)	0.17

Supplementary Table 4: Risk of progression of diabetes for each SNP, adjusted for

Genetic locus	Reported OR	interaction SNP*TX	TX ADJUSTED HR (95% CI)	P- VAL
<i>TCF7L2</i>	1.37	N	1.16 (1.02-1.32)	0.02
<i>CDKN2A/2B</i>	1.26	N	0.96 (0.81-1.13)	0.63
<i>CDKAL1</i>	1.25	N	1.02 (0.91-1.15)	0.74
<i>PPARG</i>	1.18	N	1.17 (0.94-1.47)	0.17
<i>IGF2BP2</i>	1.17	N	1.09 (0.98-1.22)	0.12
<i>HHEX</i>	1.17	N	0.99 (0.88-1.12)	0.92
<i>KCNJ11</i>	1.16	Y		
<i>SLC30A8</i>	1.15	N	1.08 (0.94-1.24)	0.28
<i>THADA</i>	1.15	N	0.94 (0.80-1.12)	0.5
<i>CENTD2</i>	1.14	N	1.16 (0.94-1.43)	0.17
<i>NOTCH2</i>	1.13	N	0.89 (0.75-1.05)	0.15
<i>ADCY5</i>	1.12	N	0.94 (0.81-1.08)	0.37
<i>WFS1</i>	1.11	N	1.00 (0.89-1.13)	1
<i>CDC123</i>	1.11	N	0.92 (0.80-1.06)	0.27
<i>IRS1</i>	1.11	N	0.93 (0.82-1.05)	0.23
<i>CHCHD9</i>	1.11	N	1.06 (0.85-1.32)	0.61
<i>JAZF1</i>	1.10	N	0.96 (0.85-1.08)	0.47
<i>HNF1B</i>	1.10	N	1.14 (1.02-1.28)	0.02
<i>HMGA2</i>	1.10	N	1.06 (0.92-1.23)	0.43
<i>ADAMTS9</i>	1.09	N	0.98 (0.86-1.12)	0.8
<i>TSPAN8</i>	1.09	N	1.05 (0.93-1.20)	0.44
<i>MTNR1B</i>	1.09	N	1.07 (0.94-1.22)	0.3
<i>BCL11A</i>	1.08	N	0.96 (0.85-1.07)	0.47
<i>SLC22A18AS</i>	1.08	N	1.00 (0.89-1.13)	0.97
<i>ZBED3</i>	1.08	N	0.97 (0.85-1.10)	0.61
<i>PROX1</i>	1.07	N	0.87 (0.78-0.98)	0.02
<i>GCK</i>	1.07	N	0.98 (0.86-1.13)	0.8
<i>TSGA13</i>	1.07	N	0.98 (0.87-1.10)	0.73
<i>VPS33B</i>	1.07	N	1.06 (0.95-1.18)	0.29
<i>HNF1A</i>	1.07	Y		
<i>DGKB</i>	1.06	N	0.94 (0.84-1.06)	0.33
<i>GCKR</i>	1.06	N	1.05 (0.93-1.19)	0.4
<i>PLEKHF2</i>	1.06	Y		
<i>BCL2A1</i>	1.06	N	1.03 (0.92-1.15)	0.63

SNP= single nucleotide polymorphism

TX= treatment

justed for treatment, and presented by treatment arm

PLACEBO HR (95% CI)	P- VAL	METFORMIN HR (95% CI)	P- VAL	LIFESTYLE HR(95% CI)
1.23 (1.01-1.50)	0.040	1.23 (0.98-1.54)	0.070	1.08 (0.83-1.40)
0.80 (0.62-1.02)	0.07	1.20 (0.87-1.65)	0.28	1.08 (0.77-1.52)
1.01 (0.84-1.21)	0.91	1.04 (0.84-1.29)	0.7	0.92 (0.71-1.20)
1.21 (0.85-1.74)	0.29	1.35 (0.88-2.05)	0.17	0.92 (0.59-1.42)
0.94 (0.78-1.15)	0.56	1.23 (0.99-1.52)	0.06	1.15 (0.90-1.48)
1.11 (0.92-1.33)	0.29	0.88 (0.71-1.10)	0.27	0.92 (0.72-1.18)
0.85 (0.69-1.05)	0.13	1.23 (0.98-1.56)	0.08	0.86 (0.65-1.13)
1.06 (0.85-1.32)	0.61	1.23 (0.96-1.58)	0.1	0.95 (0.72-1.24)
1.16 (0.88-1.53)	0.3	0.77 (0.58-1.02)	0.07	1.02 (0.68-1.53)
1.25 (0.88-1.79)	0.21	1.13 (0.78-1.65)	0.52	0.99 (0.66-1.49)
0.96 (0.75-1.23)	0.75	0.80 (0.59-1.09)	0.16	0.79 (0.53-1.19)
0.96 (0.77-1.20)	0.73	0.94 (0.74-1.20)	0.61	0.88 (0.65-1.19)
0.99 (0.82-1.21)	0.95	0.88 (0.72-1.08)	0.21	1.19 (0.92-1.55)
0.88 (0.71-1.10)	0.260	0.99 (0.76-1.28)	0.91	1.00 (0.75-1.34)
0.91 (0.75-1.11)	0.37	0.96 (0.78-1.20)	0.74	0.80 (0.61-1.05)
0.97 (0.70-1.35)	0.87	1.25 (0.82-1.90)	0.31	1.03 (0.66-1.60)
0.95 (0.79-1.15)	0.63	0.97 (0.79-1.20)	0.780	0.97 (0.75-1.25)
1.22 (1.01-1.46)	0.04	1.14 (0.93-1.39)	0.21	0.98 (0.77-1.25)
1.13 (0.90-1.42)	0.3	1.05 (0.79-1.40)	0.73	0.81 (0.55-1.19)
1.03 (0.84-1.26)	0.77	0.87 (0.70-1.09)	0.22	1.13 (0.86-1.47)
0.95 (0.77-1.16)	0.6	1.10 (0.88-1.39)	0.4	1.24 (0.95-1.61)
1.30 (1.05-1.60)	0.02	1.02 (0.80-1.29)	0.9	1.02 (0.77-1.34)
0.98 (0.82-1.17)	0.83	0.88 (0.72-1.08)	0.22	1.10 (0.86-1.40)
1.05 (0.86-1.27)	0.65	0.87 (0.70-1.08)	0.21	1.24 (0.96-1.60)
1.04 (0.86-1.26)	0.68	0.99 (0.78-1.24)	0.91	0.87 (0.66-1.15)
0.85 (0.71-1.03)	0.1	0.94 (0.76-1.17)	0.58	0.84 (0.65-1.08)
0.89 (0.71-1.11)	0.29	1.16 (0.91-1.48)	0.22	0.95 (0.71-1.28)
1.06 (0.88-1.28)	0.56	0.80 (0.64-1.00)	0.05	0.98 (0.76-1.26)
0.89 (0.73-1.08)	0.24	1.32 (1.05-1.67)	0.02	0.98 (0.75-1.29)
1.01 (0.79-1.29)	0.93	1.33 (1.00-1.78)	0.05	0.64 (0.47-0.87)
0.97 (0.81-1.16)	0.720	0.90 (0.73-1.10)	0.310	0.98 (0.77-1.25)
1.05 (0.86-1.29)	0.62	0.98 (0.79-1.22)	0.870	1.07 (0.84-1.38)
1.28 (1.06-1.54)	0.01	1.14 (0.93-1.40)	0.2	0.91 (0.71-1.16)
1.08 (0.90-1.30)	0.43	1.03 (0.83-1.27)	0.81	1.13 (0.88-1.46)

P-

VAL

0.57

0.65

0.56

0.7

0.26

0.52

0.27

0.7

0.94

0.96

0.26

0.41

0.190

0.97

0.11

0.9

0.82

0.870

0.28

0.38

0.110

0.92

0.46

0.09

0.33

0.17

0.75

0.87

0.91

0

0.9

0.57

0.45

0.34

Supplementary Table 5: Regression to NGR for each individual SNP adjust

Genetic locus	Reported OR	interaction SNP*TX	TX ADJUSTED HR (95% CI)	P- VAL
<i>TCF7L2</i>	1.37	N	0.87 (0.76-1.01)	0.06
<i>CDKN2A/2B</i>	1.26	N	0.88 (0.74-1.05)	0.15
<i>CDKAL1</i>	1.25	N	0.94 (0.82-1.07)	0.36
<i>PPARG</i>	1.18	N	0.87 (0.70-1.10)	0.24
<i>HHEX</i>	1.17	Y		
<i>IGF2BP2</i>	1.17	N	1.08 (0.96-1.21)	0.23
<i>KCNJ11</i>	1.16	Y		
<i>SLC30A8</i>	1.15	N	0.89 (0.77-1.02)	0.1
<i>THADA</i>	1.15	N	1.14 (0.93-1.40)	0.19
<i>CENTD2</i>	1.14	N	0.89 (0.72-1.10)	0.27
<i>NOTCH2</i>	1.13	N	0.98 (0.82-1.17)	0.83
<i>ADCY5</i>	1.12	N	1.03 (0.87-1.21)	0.750
<i>WFS1</i>	1.11	N	0.98 (0.86-1.12)	0.77
<i>CDC123</i>	1.11	N	0.90 (0.77-1.06)	0.22
<i>IRS1</i>	1.11	N	1.04 (0.91-1.19)	0.54
<i>CHCHD9</i>	1.11	N	0.96 (0.76-1.22)	0.76
<i>JAZF1</i>	1.10	N	1.04 (0.91-1.19)	0.550
<i>HNF1B</i>	1.10	N	1.00 (0.88-1.13)	0.99
<i>HMGA2</i>	1.10	N	1.02 (0.86-1.20)	0.820
<i>ADAMTS9</i>	1.09	N	0.98 (0.85-1.12)	0.73
<i>TSPAN8</i>	1.09	N	0.94 (0.81-1.09)	0.43
<i>MTNR1B</i>	1.09	Y		
<i>BCL11A</i>	1.08	N	0.99 (0.88-1.13)	0.94
<i>SLC22A18AS</i>	1.08	N	1.01 (0.89-1.15)	0.85
<i>ZBED3</i>	1.08	N	0.89 (0.77-1.03)	0.12
<i>PROX1</i>	1.07	N	0.99 (0.87-1.12)	0.87
<i>GCK</i>	1.07	N	0.81 (0.69-0.95)	0.01
<i>TSGA13</i>	1.07	N	0.91 (0.80-1.04)	0.16
<i>VPS33B</i>	1.07	N	0.96 (0.86-1.08)	0.51
<i>HNF1A</i>	1.07	N	0.95 (0.80-1.12)	0.51
<i>DGKB</i>	1.06	N	1.01 (0.89-1.15)	0.89
<i>GCKR</i>	1.06	N	1.02 (0.89-1.17)	0.76
<i>PLEKHF2</i>	1.06	Y		
<i>BCL2A1</i>	1.06	N	1.08 (0.95-1.23)	0.22

NGR= normal glucose regulation

SNP= single nucleotide polymorphism

TX= treatment

sted for treatment, and presented in each treatment arm

PLACEBO HR (95% CI)	P- VAL	METFORMIN HR (95% CI)	P- VAL	LIFESTYLE HR(95% CI)	P- VAL
0.86 (0.64-1.17)	0.35	0.73 (0.55-0.97)	0.03	0.90 (0.73-1.11)	0.32
0.82 (0.56-1.18)	0.29	0.85 (0.59-1.22)	0.38	0.78 (0.60-1.02)	0.07
0.99 (0.75-1.32)	0.97	0.94 (0.72-1.22)	0.62	0.90 (0.74-1.11)	0.330
1.17 (0.71-1.92)	0.53	0.76 (0.49-1.18)	0.22	0.80 (0.56-1.13)	0.200
1.19 (0.89-1.58)	0.24	0.87 (0.67-1.13)	0.31	0.80 (0.65-0.97)	0.02
1.13 (0.85-1.48)	0.4	1.23 (0.95-1.60)	0.11	1.00 (0.82-1.22)	1
1.09 (0.81-1.47)	0.57	0.88 (0.65-1.19)	0.42	1.08 (0.88-1.34)	0.46
0.87 (0.63-1.19)	0.38	0.76 (0.57-1.01)	0.06	0.88 (0.71-1.09)	0.23
1.06 (0.69-1.61)	0.8	1.17 (0.80-1.70)	0.42	1.21 (0.87-1.68)	0.25
0.81 (0.51-1.29)	0.37	0.77 (0.51-1.15)	0.2	0.94 (0.68-1.29)	0.690
0.91 (0.63-1.33)	0.63	0.99 (0.71-1.37)	0.94	0.95 (0.71-1.28)	0.76
1.07 (0.76-1.51)	0.7	1.00 (0.74-1.34)	0.97	1.11 (0.86-1.42)	0.42
0.98 (0.73-1.30)	0.87	1.02 (0.79-1.31)	0.89	0.96 (0.79-1.18)	0.700
1.05 (0.76-1.46)	0.75	0.73 (0.53-1.00)	0.05	0.92 (0.72-1.16)	0.46
1.24 (0.95-1.63)	0.12	1.07 (0.83-1.37)	0.61	0.97 (0.79-1.19)	0.76
0.97 (0.60-1.56)	0.890	0.87 (0.54-1.39)	0.56	1.07 (0.75-1.53)	0.710
1.08 (0.82-1.42)	0.59	1.05 (0.82-1.35)	0.7	1.06 (0.86-1.30)	0.61
1.15 (0.87-1.51)	0.33	0.85 (0.67-1.09)	0.2	1.07 (0.88-1.30)	0.49
1.07 (0.75-1.53)	0.7	1.12 (0.80-1.58)	0.5	0.93 (0.69-1.24)	0.6
0.84 (0.64-1.12)	0.24	0.97 (0.75-1.27)	0.83	1.00 (0.81-1.24)	0.99
1.03 (0.76-1.38)	0.86	0.83 (0.62-1.11)	0.2	0.99 (0.79-1.23)	0.9
0.54 (0.37-0.79)	0	0.80 (0.59-1.08)	0.15	0.90 (0.72-1.12)	0.34
1.07 (0.82-1.40)	0.6	0.91 (0.72-1.16)	0.45	0.97 (0.80-1.18)	0.77
0.99 (0.75-1.32)	0.96	1.19 (0.91-1.54)	0.2	0.98 (0.80-1.21)	0.88
0.75 (0.56-1.01)	0.060	0.95 (0.73-1.26)	0.74	0.87 (0.70-1.07)	0.19
0.91 (0.70-1.19)	0.49	1.01 (0.78-1.33)	0.92	1.03 (0.84-1.26)	0.79
0.79 (0.57-1.10)	0.17	0.71 (0.52-0.96)	0.03	0.76 (0.60-0.97)	0.03
0.85 (0.65-1.11)	0.22	0.82 (0.62-1.07)	0.14	0.99 (0.81-1.21)	0.95
0.93 (0.70-1.23)	0.61	0.83 (0.63-1.10)	0.2	1.01 (0.82-1.25)	0.9
0.76 (0.54-1.06)	0.11	1.01 (0.75-1.37)	0.94	0.98 (0.75-1.28)	0.89
0.88 (0.67-1.15)	0.36	1.21 (0.95-1.55)	0.13	1.00 (0.82-1.21)	0.97
1.10 (0.82-1.49)	0.53	0.98 (0.75-1.27)	0.87	1.03 (0.84-1.27)	0.74
0.82 (0.63-1.07)	0.15	1.05 (0.82-1.34)	0.69	1.12 (0.92-1.37)	0.27
1.10 (0.83-1.46)	0.51	1.11 (0.86-1.42)	0.43	1.05 (0.86-1.29)	0.61

